Serum human chorionic somatomammotropin in unaborted hydatidiform mole.

Area of Science:

• Reproductive Endocrinology
• Maternal-Fetal Medicine
• Gynecologic Oncology

Background:

• Hydatidiform mole is a gestational trophoblastic neoplasm.
• Accurate monitoring of molar pregnancies is crucial for early detection of complications.
• Human chorionic somatomammotropin (hCS) is a placental hormone with potential as a biomarker.

Purpose of the Study:

• To investigate the relationship between serum human chorionic somatomammotropin (hCS) levels and gestational age in patients with intact, unaborted hydatidiform mole.
• To determine if serum hCS levels correlate with uterine size or serum human chorionic gonadotropin (hCG) levels.
• To assess the utility of serum hCS as a predictor of malignant sequelae, such as choriocarcinoma.

Main Methods:

• Serum hCS was measured using radioimmunoassay in 35 patients with intact, unaborted hydatidiform mole.
• Serum hCG was quantified using a hemagglutination inhibition method.
• Correlations between serum hCS, gestational age, uterine size, and serum hCG were analyzed.

Main Results:

• Serum hCS levels significantly increased with advancing gestational age in molar pregnancies.
• A significant positive correlation was observed between serum hCS levels and uterine size (r = +0.5183; P = 0.0025).
• No significant correlation was found between serum hCS and serum hCG levels. Serum hCS levels in a patient who developed choriocarcinoma were not significantly different from others.

Conclusions:

• Peripheral serum hCS levels increase with gestational age in molar pregnancies.
• Serum hCS levels are related to the mass of molar tissue, independent of serum hCG levels.
• Serum hCS is a poor predictor of malignant sequelae in hydatidiform mole.